1887
  1. Home
  2. Eurosurveillance
  3. Volume 27, Issue 31, 04/Aug/2022
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Functional immunity (defined here as serum neutralising capacity) critically contributes to conferring protection against SARS-CoV-2 infection and severe COVID-19. This cross-sectional analysis of a prospective, population-based cohort study included 1,894 randomly-selected 16 to 99-year-old participants from two Swiss cantons in March 2022. Of these, 97.6% (95% CI: 96.8–98.2%) had anti-spike IgG antibodies, and neutralising capacity was respectively observed for 94%, 92% and 88% against wild-type SARS-CoV-2, Delta and Omicron variants. Studying functional immunity to inform and monitor vaccination campaigns is crucial.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.31.2200561
2022-08-04
2024-12-30
/content/10.2807/1560-7917.ES.2022.27.31.2200561
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/31/eurosurv-27-31-1.html?itemId=/content/10.2807/1560-7917.ES.2022.27.31.2200561&mimeType=html&fmt=ahah

References

  1. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021;326(20):2043-54.  https://doi.org/10.1001/jama.2021.19499  PMID: 34734975 
  2. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021;385(24):e84.  https://doi.org/10.1056/NEJMoa2114583  PMID: 34614326 
  3. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med. 2022;386(13):1207-20.  https://doi.org/10.1056/NEJMoa2118691  PMID: 35172051 
  4. Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, Paul Chourdhury R, et al. , DMID 21-0012 Study Group. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022;3(7):100679.  https://doi.org/10.1016/j.xcrm.2022.100679  PMID: 35798000 
  5. Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. J Med Virol. 2022;94(7):2969-76.  https://doi.org/10.1002/jmv.27697  PMID: 35246846 
  6. West EA, Anker D, Amati R, Richard A, Wisniak A, Butty A, et al. Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland. Int J Public Health. 2020;65(9):1529-48.  https://doi.org/10.1007/s00038-020-01494-0  PMID: 33098441 
  7. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81.  https://doi.org/10.1016/j.jbi.2008.08.010  PMID: 18929686 
  8. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.  https://doi.org/10.1016/j.jbi.2019.103208  PMID: 31078660 
  9. Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. J Virol. 2021;95(3):e01828-20.  https://doi.org/10.1128/JVI.01828-20  PMID: 33144321 
  10. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313-9.  https://doi.org/10.1016/S0140-6736(20)31304-0  PMID: 32534626 
  11. Fenwick C, Turelli P, Pellaton C, Farina A, Campos J, Raclot C, et al. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Sci Transl Med. 2021;13(605):eabi8452.  https://doi.org/10.1126/scitranslmed.abi8452  PMID: 34257144 
  12. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. OurWorldInData.org. [Accessed 18 May 2022]. Available from: https://ourworldindata.org/covid-hospitalizations#licence.
  13. European Centre for Disease Prevention and Control (ECDC). Data on hospital and ICU admission rates and current occupancy for COVID-19. Stockholm: ECDC; Jul 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/download-data-hospital-and-icu-admission-rates-and-current-occupancy-covid-19
  14. Office for National Statistics (ONS). Coronavirus (COVID-19) latest insights: Antibodies 2022. Newport: ONS; Jul 2022. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/antibodies
  15. Nguyen D, Simmonds P, Steenhuis M, Wouters E, Desmecht D, Garigliany M, et al. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Euro Surveill. 2021;26(27):2100568.  https://doi.org/10.2807/1560-7917.ES.2021.26.27.2100568  PMID: 34240697 
  16. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-11.  https://doi.org/10.1038/s41591-021-01377-8  PMID: 34002089 
  17. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(17):606-8.  https://doi.org/10.15585/mmwr.mm7117e3  PMID: 35482574 
  18. Shields AM, Faustini SE, Hill HJ, Al-Taei S, Tanner C, Ashford F, et al. increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: An update from the COV-AD Study. Front Immunol. 2022;13:912571. PMID: 35720400 
  19. Aziz NA, Corman VM, Echterhoff AKC, Müller MA, Richter A, Schmandke A, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nat Commun. 2021;12(1):2117.  https://doi.org/10.1038/s41467-021-22351-5  PMID: 33837204 
  20. Topol EJ, Iwasaki A. Operation Nasal Vaccine—Lightning speed to counter COVID-19. American Association for the Advancement of Science; 2022. p. eadd9947.
Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Rebecca+Amati&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Amati Rebecca</a>, <a href="/search?value1=Anja+Frei&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Frei Anja</a>, <a href="/search?value1=Marco+Kaufmann&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kaufmann Marco</a>, <a href="/search?value1=Serena+Sabatini&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sabatini Serena</a>, <a href="/search?value1=C%C3%A9line+Pellaton&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pellaton Céline</a>, <a href="/search?value1=Jan+Fehr&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fehr Jan</a>, <a href="/search?value1=Emiliano+Albanese&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Albanese Emiliano</a>, <a href="/search?value1=Milo+A+Puhan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Puhan Milo A</a>, <a href="/search?value1=on+behalf+of+the+Corona+Immunitas+Research+Group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the Corona Immunitas Research Group</a></span>. Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022. <a href="/content/ecdc">Euro Surveill.</a> 2022;27(31):pii=2200561. <a href="https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2022.27.31.2200561</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 12 Jul 2022;&nbsp;&nbsp; <span class="generated">Accepted</span>: 04 Aug 2022 </span> </p>
/content/10.2807/1560-7917.ES.2022.27.31.2200561
/content/10.2807/1560-7917.ES.2022.27.31.2200561
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error